Market research
INTS Intensity Therapeutics, Inc. Common stock
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 13M
- P/E ratio
- Not available
- Analyst target
- 19.3333
- Dividend yield
- Not available
- Beta
- 3.03
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US45828J2024
- Market cap
- 13M
- P/E ratio
- Not available
- Analyst target
- 19.3333
- Dividend yield
- Not available
- Beta
- 3.03
About
About Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the INTS discussion.
No comments yet
Start a focused discussion about INTS.